| Literature DB >> 23809939 |
Darin S Carroll1, Victoria A Olson, Scott K Smith, Zach H Braden, Nishi Patel, Jason Abel, Yu Li, Inger K Damon, Kevin L Karem.
Abstract
Since the eradication of Smallpox, researchers have attempted to study Orthopoxvirus pathogenesis and immunity in animal models in order to correlate results human smallpox. A solely human pathogen, Orthopoxvirus variola fails to produce authentic smallpox illness in any other animal species tested to date. In 2003, an outbreak in the USA of Orthopoxvirus monkeypox, revealed the susceptibility of the North American black-tailed prairie dog (Cynomys ludovicianus) to infection and fulminate disease. Prairie dogs infected with Orthopoxvirus monkeypox present with a clinical scenario similar to ordinary smallpox, including prodrome, rash, and high mortality. This study examines if Black-tailed prairie dogs can become infected with O. variola and serve as a surrogate model for the study of human smallpox disease. Substantive evidence of infection is found in immunological seroconversion of animals to either intranasal or intradermal challenges with O. variola, but in the absence of overt illness. Published by Elsevier Inc.Entities:
Keywords: Animal model; Immunity; Infection; Orthopoxvirus; Prairie dog; Smallpox; Variola
Mesh:
Substances:
Year: 2013 PMID: 23809939 PMCID: PMC9533861 DOI: 10.1016/j.virol.2013.05.029
Source DB: PubMed Journal: Virology ISSN: 0042-6822 Impact factor: 3.513
Fig. 1Summary of clinical pathogenesis and stages of illness of smallpox in humans, and monkeypox in humans, prairie dogs and rhesus maquaces.
Fig. 2Photos of inoculation sites day 7 post inoculation (a) intranasally and (b) intradermally.
Fig. 3Weights of animals (in grams) post challenge, measured every 3 days.
Fig. 4ELISA of anti-Orthopoxvirus antibody in animal sera. Values are reported as post challenge (day 21) minus pre challenge (day 0) absorbance at 450 nm.
Neutralization capacity of sera at day 21 post challenge. Sera collected at day 21 was analyzed for virus neutralization capacity using the array scan system. Titers reported are that which neutralized 50% of the virus titer.
| VRV-01 IN | <1:40 |
| VRV-02 ID | <1:40 |
| VRV-03 IN | 50.45 |
| VRV-04 IN | <1:40 |
| VRV-05 IN | <1:40 |
| VRV-06 IN | 106 |
| VRV-07 ID | <1:40 |
| VRV-08 ID | 153.6 |
| VRV-09 ID | 48.07 |
| VRV-10 ID | 154 |
| VRV-11 IN contl | <1:40 |
| VRV-12 ID contl | <1:40 |
| <1:40 | |
| 6103 |
Naïve sera and prebleeds from all animals tested <1:40 dilution for 50% viral neutralization.
VIG titer giving 50% viral neutralization; R²=0.9699.